LivaNova PLC
LIVN
주식 순위
#3843
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
주가
$78.25
마지막 동기화: 2026-10-21
시가총액
$4.30B
변동 (1일)
-1.84%
변동 (1년)
42.65%
국가
GB
거래 LivaNova PLC (LIVN)
카테고리
Healthcare
LivaNova PLC (LIVN)의 매출
Jun 2026 기준 매출 TTM: $1.47B
LivaNova PLC의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.47B입니다. 2023년에 회사는 $1.15B의 수익을 올렸으며 이는 2022년의 $1.02B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
LivaNova PLC의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.47B | 17.40% |
| 2024 | $1.25B | 8.66% |
| 2023 | $1.15B | 12.89% |
| 2022 | $1.02B | -1.31% |
| 2021 | $1.04B | 10.82% |
| 2020 | $934.24M | -13.83% |
| 2019 | $1.08B | -2.06% |
| 2018 | $1.11B | 9.35% |
| 2017 | $1.01B | -16.61% |
| 2016 | $1.21B | 316.35% |
| 2015 | $291.56M | 3.38% |
| 2014 | $282.01M | 10.89% |
| 2013 | $254.32M | 16.39% |
| 2012 | $218.50M | 14.72% |
| 2011 | $190.46M | 13.52% |
| 2010 | $167.78M | 16.83% |
| 2009 | $143.60M | 18.45% |
| 2008 | $121.23M | -7.44% |
| 2007 | $130.97M | 6.10% |
| 2006 | $123.44M | 19.33% |
| 2005 | $103.44M | -6.57% |
| 2004 | $110.72M | 5.99% |
| 2003 | $104.47M | 49.00% |
| 2002 | $70.11M | 46.40% |
| 2000 | $47.89M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.59B | 3,065.79% |
US
|
|
| $35.48B | 2,311.40% |
IE
|
|
| $25.84B | 1,655.81% |
US
|
|
| $21.00B | 1,326.83% |
US
|
|
| - | - |
DE
|
